Drug Type siRNA |
Synonyms SGB 9768 |
Target |
Mechanism C3 inhibitors(Complement C3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
C3 glomerulopathy | Phase 1 | CN | 18 Jul 2024 | |
Glomerulonephritis, IGA | Phase 1 | CN | 18 Jul 2024 | |
Glomerulonephritis, Membranoproliferative | Phase 1 | CN | 18 Jul 2024 | |
Immune System Diseases | IND Approval | NZ | 27 Feb 2024 |
NCT06501573 (NEWS) Manual | Phase 1 | - | 55 | kwcvlnjagu(amvdmdmzck) = SGB-9768表现出良好的安全性和耐受性。 xtltzgdynf (ignxhzyebq ) View more | Positive | 11 Dec 2024 | |
Placebo |